2,3-Dihydro-3-(2-methylprop-1-yl)-2-thioxoquinazolin-4(1H)-one, 3-Isobutyl-4-oxo-1,2,3,4-tetrahydro-2-thioxoquinazoline
3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone
CAS: 117038-39-8
Molecular Formula: C12H14N2OS
2,3-Dihydro-3-(2-methylprop-1-yl)-2-thioxoquinazolin-4(1H)-one, 3-Isobutyl-4-oxo-1,2,3,4-tetrahydro-2-thioxoquinazoline - Names and Identifiers
2,3-Dihydro-3-(2-methylprop-1-yl)-2-thioxoquinazolin-4(1H)-one, 3-Isobutyl-4-oxo-1,2,3,4-tetrahydro-2-thioxoquinazoline - Physico-chemical Properties
| Molecular Formula | C12H14N2OS |
| Molar Mass | 234.32 |
| Melting Point | 211.5～213.5℃ |
| Storage Condition | Room Temprature |
| Sensitive | IRRITANT |
| MDL | MFCD00175721 |
2,3-Dihydro-3-(2-methylprop-1-yl)-2-thioxoquinazolin-4(1H)-one, 3-Isobutyl-4-oxo-1,2,3,4-tetrahydro-2-thioxoquinazoline - Introduction
3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone is an organic compound with the formula C14H16N2OS. The following is a description of its nature, use, preparation and safety information:
Nature:
-Appearance: 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone as a white crystalline solid.
-Solubility: It is slightly soluble in water and soluble in organic solvents such as ethanol and dimethyl sulfoxide.
Use:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone is a heterocyclic compound containing thiazole ring and quinazoline ring, which has a variety of biological activities. It has potential anti-tumor, anti-inflammatory and antibacterial activities in the field of medicine. It is also used as an important intermediate in organic synthesis.
Preparation Method:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone can be synthesized by various routes. A common method is the reaction of 2-aminobenzoyl propionic acid quaternary ammonium hydrofluoride with sulfonyl chloride to obtain the product after removal of the quaternary ammonium salt under alkaline conditions.
Safety Information:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone specific safety information may vary depending on the conditions and use, so the relevant safety information and applicable regulations should be consulted before use.
-Avoid inhaling its dust or vapor, and avoid contact with skin and eyes. Appropriate protective gloves and goggles should be worn when operating it.
-During storage and handling, comply with relevant chemical safety regulations and keep them away from combustibles and oxidants.
-If the compound is ingested or inhaled by mistake, seek medical attention immediately and provide the information required by the doctor.
Nature:
-Appearance: 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone as a white crystalline solid.
-Solubility: It is slightly soluble in water and soluble in organic solvents such as ethanol and dimethyl sulfoxide.
Use:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone is a heterocyclic compound containing thiazole ring and quinazoline ring, which has a variety of biological activities. It has potential anti-tumor, anti-inflammatory and antibacterial activities in the field of medicine. It is also used as an important intermediate in organic synthesis.
Preparation Method:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone can be synthesized by various routes. A common method is the reaction of 2-aminobenzoyl propionic acid quaternary ammonium hydrofluoride with sulfonyl chloride to obtain the product after removal of the quaternary ammonium salt under alkaline conditions.
Safety Information:
- 3-Isobutyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone specific safety information may vary depending on the conditions and use, so the relevant safety information and applicable regulations should be consulted before use.
-Avoid inhaling its dust or vapor, and avoid contact with skin and eyes. Appropriate protective gloves and goggles should be worn when operating it.
-During storage and handling, comply with relevant chemical safety regulations and keep them away from combustibles and oxidants.
-If the compound is ingested or inhaled by mistake, seek medical attention immediately and provide the information required by the doctor.
Last Update：2024-04-09 19:06:00
